[68Ga]Ga-NECT-224 PET/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
A 64-year-old man with metachronous metastatic urothelial carcinoma originating from the right renal pelvis underwent nectin-4-targeted [ 68 Ga]Ga-NECT-224 PET/CT prior to initiation of nectin-4-targeted antibody-drug conjugate (ADC) therapy with enfortumab-vedotin (PADCEV), in combination with pembrolizumab. A CT follow-up after 3 months of ADC therapy showed a progressive adrenal metastasis. Subsequent [ 68 Ga]Ga-NECT-224 PET/CT restaging revealed multiple new lesions with intense nectin-4 expression. This case illustrates the potential of [ 68 Ga]Ga-NECT-224 PET/CT to visualize heterogeneous nectin-4 expression, its potential in therapy guidance, and highlights the need for theranostic strategies in patients retaining target expression despite cytotoxic therapy resistance.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 732-734 |
| Number of pages | 3 |
| Journal | Clinical nuclear medicine |
| Volume | 51 |
| Issue number | 8 |
| Publication status | Published - 1 Aug 2026 |
| Peer-reviewed | Yes |
External IDs
| ORCID | /0000-0002-6432-5694/work/219976896 |
|---|---|
| unpaywall | 10.1097/rlu.0000000000006528 |
Keywords
Keywords
- Immunoconjugates/therapeutic use, Humans, Middle Aged, Antibodies, Monoclonal/therapeutic use, Male, Gene Expression Regulation, Neoplastic/drug effects, Disease Progression, Positron Emission Tomography Computed Tomography, Cell Adhesion Molecules/metabolism, Gallium Radioisotopes, Urologic Neoplasms/diagnostic imaging, Urothelium/pathology, Nectins/metabolism